"Norway's Wealth Fund Eyes Novo Nordisk and Eli Lilly for Trillion-Dollar Club"
Norway's wealth fund suggested that Danish drugmaker Novo Nordisk and U.S. company Eli Lilly could become the first healthcare members of the trillion-dollar club, as demand for diabetes and weight loss drugs skyrockets. Novo Nordisk's market valuation surpassed $500 billion, while Eli Lilly stands at roughly $612 billion. The fund holds stakes in both companies and is closely monitoring the potential for weight loss drugs to treat chronic kidney disease, obstructive sleep apnea, and Alzheimer's disease. The global weight loss drug market is expected to grow to about $100 billion by the end of the decade.